Development of metabotropic glutamate receptor ligands for neuro-imaging

Current Medical Imaging Reviews

Volumn 3, Issue 3, 2007, Pages 186-205

  Wang, Ji Quan ^a   Brownell, Anna Liisa ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Allosteric modulator; Glutamate; Metabotropic glutamate receptor; mGluR5; Positron emission tomography; Tracer

Indexed keywords

2 [(3 METHOXYPHENYL)ETHYNYL] 6 METHYLPYRIDINE C 11; 2 FLUORO 5 [2 (2 METHYLTHIAZOL 4 YL)ETHYNYL]PYRIDINE F 18; 2 METHYL 6 (2 PHENYLETHYNYL)PYRIDINE C 11; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 2BETA CARBOMETHOXY 3BETA (4 FLUOROPHENYL)TROPANE C 11; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 ETHYL 2 METHYL 6 QUINOLINYL(4 METHOXYCYCLOHEXYL)METHANONE C 11; 3 METHOXY 5 [(2 PYRIDYL)ETHYNYL]PYRIDINE C 11; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; BAY 36 7620; CARBON 11; FLUORINE 18; GLUTAMIC ACID; JNJ 16259685; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 6; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; QUINOLINE DERIVATIVE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENERGIC TRANSMISSION; AMYOTROPHIC LATERAL SCLEROSIS; BINDING AFFINITY; BINDING SITE; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC VALUE; DOPAMINERGIC TRANSMISSION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUNTINGTON CHOREA; IC 50; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 34547878730     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340507781387059     Document Type: Review

References (97)

1. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41: 135-44.
2. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31-9.
3. Oney JW. Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW, McGeer PL Ed, Kainic acid as a tool in neurobiology. New York, Raven Press. 1978; 95-121.
4. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Opthalmol 1957; 58: 193-201.
5. Kozikowski AP, Steensma D, Araldi GL, et al. Synthesis and biology of the confortionally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist. J Med Chem 1998; 41: 1641-50.
6. Pin J-P, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003; 98: 325-54.
7. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999; 38: 1431-76.
8. Layton ME. Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1). Curr Top Med Chem 2005; 5: 859-67.
9. Slassi A, Isaac M, Edwards L, et al. Recent advances in noncompetitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr Top Med Chem 2005; 5: 897-911.
10. Rudd MT, McCauley JA. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem 2005; 5: 869-84.
11. Marino MJ, Hess JF, Liverton N. Targeting the metabotropic glutamate receptor mGluR4 for the treatment of diseases of the central nervous system. Curr Top Med Chem 2005; 5: 885-95.
12. Yang Z-Q. Agonists and antagonists for group III metabotropic glutamate receptors 6, 7, and 8. Curr Top Med Chem 2005; 5: 913-8.
13. Williams Jr DL, Lindsley CW. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr Top Med Chem 2005; 5: 825-46.
14. Kew JNC. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 2004; 104: 233-44.
15. Guitart X, Khurdayan VK. Metabotropic glutamate receptors as therapeutic targets. Drug News Perspect 2005; 18: 587-93.
16. Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005; 97: 202-13.
17. Niswender CM, Jones CK, Conn PJ. New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem 2005; 5: 847-57.
18. Annoura H, Fukunaga A, Uesugi M, Tatsuoka T, Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg Med chem Lett 1996; 6: 763-6.
19. Pin JP, Duvoisin R. Review: neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995; 34: 1-26.
20. Schoepp DD, Goldsworthy J, Johnson BG, Salhoff CR, Baker SR. 3,5-dihydroxyphenylglycine is a highly selective agonist for phosphorinositide-linked metabotropic glutamate receptors in the rat hippocampus. J Neurochem 1994; 63: 769-72.
21. Tanabe Y, Nomura A, Masu M, Shigemoto R, Mizuno N, Nakanishi S. Signal transduction, pharmacological properties, and expression patters of two metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 1997; 13: 1372-8.
22. Conn J, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37: 205-37.
23. Blakely RD. Neurobiology. Dopamine's reversal of fortune. Science 2001; 293: 2407-9.
24. Popoli P, Pezzola A, Torvinen M, et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 2001; 25: 505-13.
25. Marino MJ, Wittmann M, Bradley SR, Hubert GW, Smith Y, Conn PJ. Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. J Neurosci 2001; 21: 7001-12.
26. Keyvani K, Bosse F, Reinecke S, Paulus W, Witte OW. Postlesional transcriptional regulation of metabotropic glutamate receptors: implications for plasticity and excitotoxicity. Acta Neuropathol 2001; 101: 79-84.
27. O'Neill MJ. Pharmacology and neuroprotective actions of mGlu receptor ligands. Dev Med Child Neurol Suppl. 2001; 86: 13-5.
28. Aguirre JA, Andbjer B, Gonzalez-Baron S, et al. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury. Neuroreport 2001; 12: 2615-7.
29. Rouse ST, Marino MJ, Bradley SR, Award H, Wittmann M, Conn PK. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 2000; 88: 427-35.
30. Rao AM, Hatcher JF, Dempsey RJ. Neuroprotection by group I metabotropic glutamate receptor antagonist in forebrain ischemia of gerbil. Neurosci Lett 2000; 293: 1-4.
31. Calabresi P, Centonze D, Pisani A, Bernardi G. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp Neurol 1999; 158: 97-108.
32. Micheli F, Fabio RD, Cavanni P, et al. Synthesis and pharmacological characterization of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem 2003; 11: 171-83.
33. Litschig S, Gasparini F, Rueegg D, et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 1999; 55: 453-61.
34. Ott D, Floersheim P, Inderbitzin W, et al. Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (±)-2-hydroxyiminola,2-dihydro-1H-7-oxacyclopropa i b]naphthalene-7a-carboxylic acid ethyl ester. J Med Chem 2000; 43: 4428.
35. Carroll FY, Stolle A, Beart PM, et al. BAY 36-7620: a potent noncompetitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 2001; 59: 965-73.
36. Malherbe P, Kratochwil. N, Knoflach F, et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 2003; 278: 8340-7.
37. Micheli F, Di Fabio R, Bordi F, et al. 2,4-Dicarboxypyrroles as selective noncompetitive mGluR1 antagonists: further characterization of 3,5-dimethylpyrrole-2,4-dicarboxylic acid 2-propyl ester 4-(1,2,2-trimethylpropyl) ester and structure-activity relationships. Bioorg Med Chem Lett 2003; 13: 2113-8.
38. Lavreysen H, Wouters R, Bischoff F, et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 2004; 47: 961-72.
39. Mabire D, Coupa S, Adelinet C, et al. Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1R antagonists. J Med Chem 2005; 48: 2134-53.
40. 11C]methyl- 6-quinolinyl](cis-4-methoxycyclohexyl)methanone. J Med Chem 2005; 48: 5096-9.
41. Yu M, Brownell A-L. Synthesis of C-11 CPCCOMe, a potent PET ligand for imaging mGluR1 in vivo. Molecular Imaging 2002; 1:230.
42. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 2003; 63: 1082-93.
43. 2 high-affinity state with positron emission tomography. J Med Chem 2005; 48: 4153-60.
44. 11C-propyl-norapomorphine in vivo binding in Nonhuman primates. J Nucl Med 2004; 45: 338-46.
45. 1A receptor PET ligand. Bioorg Med Chem Lett 2006; 16: 2101-4.
46. 1A receptor agonist positron emission tomography ligand. J Med Chem 2006; 49: 125-34.
47. Kew JNC, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005; 179: 4-29.
48. Hemstapat K, de Paulis T, Chen Y, et al. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol 2006; 70: 616-26.
49. Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J. 9H-xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H -tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett 2005; 15: 4628-31.
50. Varney MA, Cosford ND, Jachec C, et al. SIB-1757 and SIB-1893, selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 1999; 290: 170-81.
51. Gasparini F, Lingenheohl K, Stoehr N, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999; 38: 1493-1503.
52. Cosford ND, Tehrani L, Roppe J, et al. 3-[(2-Methyl-1,3-thiazo-4-yl)-ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003; 46: 204-6.
53. Iso Y, Grajkowska E, Wroblewski JT, et al. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; Search for cocaine medications. J Med Chem 2006; 49: 1080-100.
54. 3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 2002; 12: 407-9.
55. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003; 13: 351-4.
56. Roppe JR, Wang B, Huang D, et al. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3′-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg Med Chem Lett 2004; 14: 3993-6.
57. Alagille D, Baldwin RM, Roth BL, Wroblewski JT, Grajkowska E, Tamagnan GD. Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity. Bioorg Med Chem 2005; 13: 197-209.
58. Roppe J, Smith ND, Huang D, et al. Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem 2004; 47: 4645-8.
59. Poon SF, Eastman BW, Chapman DF, et al. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]- 4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett 2004; 14: 5477-80.
60. Huang D, Poon SF, Chapman DF, et al. 2-[2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist Bioorg Med Chem Lett 2004; 14: 5473-6.
61. Wang B, Vernier J-M, Rao S, et al. Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem 2004; 12: 17-21.
62. Bonnefous C, Vernier J-M, Hutchinson JH, Chung J, Reyes-Manalo G, Kamenecka T. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett 2005; 15: 1197-200.
63. O'Brien JA, Lemaire W, Chen T-B, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 2003; 64: 731-40.
64. O'Brien JA, Lemaire W, Wittmann M, et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 2004; 309: 568-77.
65. Lindsley CW, Wisnoski DD, Leister WH, et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 2004; 47: 5825-8.
66. Kinney GG, O'Brien JA, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005; 313: 199-206.
67. de Paulis T, Hemstapat K, Chen Y, et al. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate 5 receptor in rat cortical astrocytes. J Med Chem 2006; 49: 3332-44.
68. Bessis A-S, Bonnet B, Le Poul E, Rocher J-P, Epping-Jordan M. Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5). PCT Int Appl 2005; WO 2005044797.
69. Hamill TG, Krause S, Ryan C, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 2005; 56: 205-16.
70. Zhu A, Wang X, Yu M, Wang J-Q, Brownell A-L. Evaluation of four pyridine analogs to characterize 6-OHDA induced modulation of mGluR5 function in rat brain using microPET studies. J Cereb Blood Flow Metab in press.
71. Patel S, Ndubizu O, Hamill T, et al. Screening cascade and development of potential positron emission tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol Imaging Biol 2005; 7: 314-23.
72. Krause SM, Hamill TG, Seiders TJ, et al. In vivo characterizations of PET ligands for the mGluR5 receptor in rhesus monkey. Mol Imaging Biol 2003; 5: 166.
73. 11C]Methoxy-PEPy - synthesis and initial PET evaluation in rats and monkeys in vivo. Mol Imaging Biol 2003; 5: 168.
74. Yu M, Tueckmantel W, Wang X, Zhu A, Kozikowski AP, Brownell A-L. Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynylderivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors. Nucl Med Biol 2005; 32: 631-40.
75. 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47: 698-705.
76. Yasuhara A, Sakagami K, Yoshikawa R, Chaki S, Nakamura M, Nakazato A. Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists. Bioorg Med Chem 2006; 14: 3405-20.
77. Dominguez C, Prieto L, Valli MJ, et al. Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. J Med Chem 2005; 48: 3605-12.
78. Barda DA, Wang Z-Q, Britton TC, et al. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesul- fonamide. Bioorg Med chem Lett 2004; 14: 3099-102.
79. Johnson MP, Baez M, Jagdmann Jr GE, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: Synthesis and subtype selectivity of N-(4-(2- methoxyphenoxy) phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine. J Med Chem 2003; 46: 3189-92.
80. Hu E, Chua PC, Tehrani L, et al. Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor. Bioorg Med Chem Lett 2004; 14: 5071-4.
81. Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: identification and synthesis of phenyl tetrazolylacetophenones. Bioorg Med Chem Lett 2004; 14: 5329-32.
82. Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part3: identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 2005; 15: 1565-71.
83. Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as nontetrazole containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 2004; 14: 5867-72.
84. Cube RV, Vernier J-M, Hutchinson JH, et al. 3-(2-Ethoxy-4-(4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy} phenyl) propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett 2005; 15: 2389-93.
85. Adam G, Alanine A, Goetschi E, Mutel V, Woltering JJ. Benzodiazepine derivatives. PCT Int Appl 2001; WO 0129012.
86. Gatti McArthur S, Goetschi E, Wichmann J. Imidazole derivatives. PCT Int Appl 2006; WO 2006/082002.
87. Gatti McArthur S, Goetschi E, Wichmann J, Woltering TJ. Pyrazolo-pyrimidine derivatives as mGluR2 antagonists. PCT Int Appl 2006; WO 2006/084634.
88. Britton TC, Dehlinger V, Dell CP, Dressman BA, Myers JK, Nisenbaum SE. 1-(Hetero)aryl-3-amino-pyrolidine derivatives for use as mGluR3 receptor antagonists. PCT Int Appl 2006; WO 2006/044454.
89. Maj M, Bruno V, Dragic Z, et al. Neuropharmacology 2003; 45: 895-906.
90. Mitsukawa K, Yamamoto R, Ofner S, et al. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A 2005; 102: 18712-7.
91. Takechi H, Eilers J, Konnert A. A new class of synaptic response involving calcium release in dendritic spines. Nature 1998; 396:757-60.
92. 2+ channels involves multiple receptor subtypes in cortical neurons. J Neurosci 1996; 16:36-45.
93. Pekhletski R, Gerlai R, Overstreet LS, et al. Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci 1996; 16:6364-73.
94. Ametamey SM, Trever V, Streffer J, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med 2007; 48:247-52.
95. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006; 75: 25-71.
96. Golembiowska K, Koniecny J, Ossowska K, et al. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article. Amino Acids 2002; 23:199-205.
97. Lu L, Uejima JL, Gray SM, et al. Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 2007; 61: 591-8.